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Abstract
Purpose: To study the efficacy of whole brain radiotherapy (WBRT) with radiosensitizer in
comparison with WBRT alone for patients with brain metastases in terms of overall survival,
disease progression, response to treatment and adverse effects of treatment.
Methods: A meta-analysis of randomized controlled trials (RCT) was performed in order to
compare WBRT with radiosensitizer for brain metastases and WBRT alone. The MEDLINE,
EMBASE, LILACS, and Cochrane Library databases, in addition to Trial registers, bibliographic
databases, and recent issues of relevant journals were researched. Significant reports were
reviewed by two reviewers independently.
Results: A total of 8 RCTs, yielding 2317 patients were analyzed. Pooled results from this 8 RCTs
of WBRT with radiosensitizer have not shown a meaningful improvement on overall survival
compared to WBRT alone OR = 1.03 (95% CI0.84–1.25, p = 0.77). Also, there was no difference
in local brain tumor response OR = 0.8(95% CI 0.5 – 1.03) and brain tumor progression (OR =
1.11, 95% CI 0.9 – 1.3) when the two arms were compared.
Conclusion: Our data show that WBRT with the following radiosentizers (ionidamine,
metronidazole, misonodazole, motexafin gadolinium, BUdr, efaproxiral, thalidomide), have not
improved significatively the overall survival, local control and tumor response compared to WBRT
alone for brain metastases. However, 2 of them, motexafin- gadolinium and efaproxiral have been
shown in recent publications (lung and breast) to have positive action in lung and breast carcinoma
brain metastases in association with WBRT.
Background
Brain metastases represent a sizeable health care problem.
An estimated 20–40% of cancer patients will develop
multiple brain metastases [1], and 30–40% will develop a
single metastasis [2] during the course of their illness.
Therapeutical approaches to brain metastases include sur-
gery, whole brain radiotherapy (WBRT), stereotactic radi-
osurgery (SRS), and chemotherapy. Treatment decisions
must take into account clinical prognostic factors in order
to maximize survival and neurological function whilst
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are chemical or pharmacologic agents that increase the
lethal effects of radiation if administered with it. In an
attempt to improve outcomes, studies have examined the
use of whole brain radiotherapy combined to radiosensi-
tizers [12-18]. There are many chemicals capable of ren-
dering cells or tissue more sensitive to radiation, but it
only those drugs for which there is a differential response
between the tumor and dose-limiting normal tissue that
may be of benefit radiotherapy. Dozens of clinical trials
have been performed, most of which have been inconclu-
sive or have shown results with a borderline results [19-
27]. Tsao et al. has presented the results of five rand-
omized controlled trials [5,19-23] that examined the use
of radiosensitizers in addition to WBRT. However, none
of those trials detected a benefit in terms of overall sur-
vival or brain response (CR + PR). Moreover, this meta-
analysis did not evaluate the incidence of adverse effects,
the differences on quality of life or the neurocognitive
progression. Since its publication, other studies have been
published, investigating new radiosensitizers. So, the aim
of our meta-analysis is to evaluate the outcomes and
adverse effects of the randomized clinical trials in the




The aim of this study is to analyze the efficacy of whole
brain radiotherapy plus radiosensitizer compared to
whole brain alone for patients with brain metastases in
terms of overall survival, disease progression, response to
treatment and adverse effects of treatment. Secondary
objective was to investigate the treatment effect on neuro-
logical status and quality of life.
Criteria for considering studies for this review
Types of studies
All randomised and quasi-randomised controlled trials
were eligible for inclusion.
Types of participants
Adult patients were eligible if they had TC or MRI-demon-
strated brain metastases from histologically proven solid
tumors, required WBRT, with any Karnofsky performance
status and RPA class with brain metastases originated
from solid tumors, excluding small-cell lung cancer, germ
cell tumors, and lymphomas. There were no restrictions
regarding gender or nationality. Trials of prophylactic
whole brain radiotherapy in which whole brain radiother-
apy was used with no evidence of existing brain metas-
tases were excluded. Studies that examined the use of
surgery or whole brain radiotherapy, or both, for single
brain metastases were also excluded
Types of intervention
All trials were included where adult patients were ran-
domly assigned to receive WBRT given in daily fractions,
with or without radiosensitizer.
Types of outcome measures
Data for the following outcome measures were analyzed:
The overall survival in six months. Intracranial progres-
sion-free duration was defined as the time from randomi-
zation or entry to the trial until progressive brain disease
is diagnosed. Local brain response was considered as the
percentage of patients achieved complete response (CR)
or partial response (PR) to treatment. Complete response
was defined as complete radiographic disappearance of
brain metastases. Partial response was defined as more
than 50% decrease in size of the brain metastases on CT
or MR imaging. Local brain control was reported to as the
percentage of patients with unchanged or improved serial
post-treatment CT or MRI scans judged either as a com-
plete response (CR), partial response (PR), or stable dis-
ease (SD), with improving or stable neurological
symptoms or neurological examination results. SD is
defined as a 0 to 50% decrease in size of all lesions with
stabilization neurological symptoms or neurological
examination results and stable dexamethasone dose. Pro-
gressive disease is defined as an increase in the size of any
lesion, the development of new lesions, or a decrease in
neurological symptoms or examination requiring an
increase in dexamethasone dose. Quality of life, symptom
control and neurological function assessed by any scale.
Research strategy for identification of studies
Medline and manual research was done (completed inde-
pendently and in duplicate) to identify all published
(manuscripts and abstracts) randomized controlled trials
(RCTs) that comparing WBRT plus radiosensitizer treat-
ment for brain metastases to WBRT alone. The Medline
research was done on PubMed between 1966 and 2008
with no language restrictions, using the search terms
"brain metastases", "radiotherapy" or "metastases,"
"whole brain radiotherapy" or "radiosensitizer" and
"brain radiation." The second research was done through
CancerLit, EMBASE, LILACS and the Cochrane Library to
identify randomized trials published between January
1998 and July 2007, using MeSH headings (brain metas-
tases, whole brain radiotherapy, radiosensitizer/sc {Sec-
ondary}, ex-lode Clinical Trials, clinical trial {publication
type}) and text words (brain, cancer, radiotherapy:, radi-
osensitizer, trial, and study) without language restrictions.
All the researched abstracts were screened by relevance.
Manual research was done by reviewing articles and
abstracts cited in the reference lists of identified RCTs, by
reviewing the first author's article, abstract file, from refer-
ence lists of retrieved papers, textbooks and review arti-Page 2 of 11
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Annual Meetings of the American Society of Clinical
Oncology were systematically researched for evidence rel-
evant to this meta- analysis. The selection of studies for
inclusion was carried out independently by two of the
authors (V-GA and S- EJ). Each study was evaluated for
quality using the scale of 1 to 5 proposed by Jadad [18].
When reviewers disagreed on the quality scores, discrep-
ancies were identified and a consensus was reached. Trial
data abstraction was also done independently and in
duplicate, but abstractors were not blinded to the trials'
authors or institution. Any discrepancies in data abstrac-
tion were examined further and resolved by consensus.
Data analysis
The proportion of patients surviving at six months was
treated as dichotomous data. This was estimated from
Kaplan-Meier probability curves of survival at six months.
For forest plot analyses, mortality data (the inverse of sur-
vival at six months) was plotted. An odds ratio (OR) less
than 1.0 indicated that the patients in the experimental
treatment group experienced fewer deaths compared to
those in the control group. Intracranial progression-free
duration was defined as the period during which there
was no intracranial tumor growth and no new brain
metastases. This was treated as continuous data. The het-
erogeneity of instruments used and the differences in
reporting quality of life, symptom control, and adverse
effects outcomes were described and not pooled.
Results
The electronic and manual research revealed 2016 entries.
These were screened and 38 full text articles were retrieved
for further assessment. We excluded 30 studies, as they
were either not randomized studies or were not compari-
sons of medical versus surgical treatment. The reasons for
exclusion are detailed in the excluded studies figure 1.
Eight fully published trials [19-26] examined the use of
radiosensitizers in addition to whole brain radiotherapy
(2217 patients in total). The radiosensitizers used were
lonidamide [19], metronidazole [20], misonidazole [21],
bromodeoxyuridine (BrdU) [22], and motexafin gadolin-
ium [23,24], efaproxiral [25] and thalidomide [26].
Mehta et al [23] reported on survival and neurological
outcomes. A follow-up report by Meyers et al. [27]
reported specifically on neurocognitive outcomes from
the group of patients randomized in the motexafin gado-
lium trial by Mehta et al [25] reported on the use of whole
brain radiotherapy and supplemental oxygen with or
without RSR13 (efaproxiral), a novelty in radiation sensi-
tizer that performs as a modifier of hemoglobin to facili-
tate oxygen release. Table 1 describes the characteristics of
the studies included in this meta-analysis.
Setting and participants
The radiosensitizers studied were lonidamide, metronida-
zole, misonidazole, motexafin gadolinium, bromodeoxy-
uridine (BrdU), RSR13 (efaproxiral) and thalidomide. In
regards to the outcomes of interest, none of the trials
reported on either proportion of patients who were able
to reduce their daily dexamethasone dose or duration of
reduced dexamethasone requirements. All trials used
WBRT with total dose range 30 – 37.5 Gy in 10–15 frac-
tions.
Overall survival at six months
Seven studies reported overall survival as one of the out-
comes. Altogether, the analyses included 7 trials with
1763 patients. The overall mortality rates were not
decreased for WBRT with radiosensitizer arm (517/878 =
58.8%) compared to WBRT alone arms (519/885 =
58.6%). The test for heterogeneity was not statistically sig-
nificant with p value 0.28. The overall odds ratio suggests
that there is no difference between WBRT with radiosensi-
tizer arms and WBRT alone arms in terms of overall mor-
tality rate with p value 0.77, as demonstrated in figure 2.
Local brain tumor response
Four trials [19,20,22,25] reported on local brain tumor
response rates (either complete response (CR) or partial
response (PR)). There was no significant difference (P
value 0.98) in response rate among those patients receiv-
ing only whole brain radiotherapy (135/548 = 24.6%)
and those receiving treatment with whole brain radiother-
apy and radiosensitizers (135/548 = 24.6%), OR =
0.8(95% CI 0.5 – 1.03), as figure 3.
Central nervous system progression
Four studies [19,20,22,25] had reported CNS progression
data (three published and one in abstract form), 1099
patients were included in the analysis. There were no
more CNS progression in WBRT alone (150/551 = 27.2%)
compared to WBRT with radiosensitizer (135/548 =
24.6%). The likelihood of CNS progression was 1.1-fold
higher (95% CI 0.8 – 1.4) in WBRT arms. Test for hetero-
geneity was not significant with p value of 0.15, as is in the
figure 4.
Quality of life and the neurocognitive progression
Three trials [25,27,28] reported quality of life outcomes.
In the REACH trial, the numbers and percentages of
patients with stable or improving quality of life, were
assessed by the Spitzer Questionnaire (SQI) and KPS at 1,
3, and 6 months after WBRT. A larger percentage of
patients in the efaproxiral arm had stable or improving
quality of life scores over the course of the follow-up visit.
In a subgroup analysis, Suh et al. showed that in breast
cancer patients the quality of life was improved in the
WBRT plus efaproxiral arm compared to the WBRT alonePage 3 of 11
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Flowchart according to QUOROM statement criteriaigure 1
Flowchart according to QUOROM statement criteria.
      2106    potentially eligible abstracts 
1986 abstracts excluded 
Reasons: no randomization, no valid survival data, 
metastatic small cell included, or WBRT alone group, 
and review articles 
30 trials retrieved for detail 
22 trials excluded 
Reasons: no adequate phase I I  
diagnosis, no randomization, no final 
data of trials being pubished, metastátic 
small cell cancer included or 
retrospective design 
8 trials retrieved for detail 
No more trials were found according to the 
references of these articles 
8 RCTs included at last 
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Mehta et al trial, reported no significant difference in time
to progression of brain-specific quality of life (FACT-BR)
measures in any of the treatment groups. There was also
no statistically significant difference between treatment
arms in time to neurocognitive progression on the
patients treated for whole brain radiotherapy with or
without motexafin gadolinium. Patients with lung cancer
(but not other types of cancer) who were treated with
motexafin gadolinium in addition to whole brain radio-
therapy tended to have improved memory and executive
function (P value 0.062) and improved neurological func-
tion. In the RTOG-0118, quality of life was measured by
the SQLI and the Folstein MMSE was used to determine
neurocognitive progression. SQLI and MMSE were
administered at baseline and at 2-month intervals. MMSE
was scored with a threshold value associated with neuro-
cognitive functioning (absolute cutoff level of 23) and
with the use of corrections for age and educational level.
In a secondary analysis of 156 patients neurocognitive
and quality of life outcomes were examined and Corn et
al. [27] demonstrated that in spite of the neurocognitive
decrease, QOL remained stable during treatment and fol-
low-up, and poor neurocognitive function may predict
clinical deterioration.
Adverse effects
All seven published studies that assessed the addition of
radiosensitizers to whole brain radiotherapy reported seri-
ous adverse effects. In the REACH trial, most of the treat-
ment-emergent adverse effects were grade 1 (mild) to
grade 2 (moderate) in severity in both treatment arms.
The most commonly reported grade 3 adverse effects in
efaproxiral-treated patients were hypoxemia, which was
reported in 11% of patients (29 out of 266 patients). In
the RTOG 0118 [26], most of the experienced toxicities
were not severe but they were significant enough to limit
compliance with protocol therapy. The rate of patients
experiencing Grade 3–4 treatment-related adverse events
on the thalidomide arm (39/84) was significantly higher
than the rate on the WBRT arm (11/92) (p < 0.0001). In
the SMART trial [24], published by Mehta et al. in abstract
form only, most common adverse effects were skin discol-
oration (66%), urine discoloration (35%), nausea (27%),
fatigue (21%) and hypertension (18%). However, grade
3–4 toxicity was very rare 1–4%. DeAngelis et al. [19]
found that the most common side effects of lonidamide
and WBRT were myalgia (68%), testicular pain (42%),
anorexia (26%), ototoxicity (26%), malaise or fatigue
(26%), and nausea and vomiting (19%). In the Eyre study
[20] it was reported 51% incidence of nausea and vomit-
ing compared to 3.2% in the whole brain radiotherapy
arm alone. Komarnicky et al. [19] showed that the admin-
istration of the misonidazole with WBRT was well toler-
ated and produced no grade-three neurotoxicity or
ototoxicity. Phillips et al. [22], in the RTOG 8905,
reported three fatal toxicities in 34 patients randomized to
whole brain radiotherapy with administration of the radi-
Table 1: Randomized studies of WBRT and radiosensitizers versus WBRT alone
Study Study arms No. of pts randomized Overall median survival Overall survival at 6 
months
Response (CR + PR)
DeAngelis (19) 3000 cGy/10 fr + 
lonidamine
31 4.0 m NR 37%
3000 cGy/10 fr 27 5.4 m 55%
Eyre (20) 3000 cGy/10 fr + 
metronidazole
57 2.8 m 14 27%
3000 cGy/10 fr 54 3.2 m 13 24%
RTOG-7916(21) 3000 cGy/6 fr + 
misonidazole
220 3.1 m 68 NR
3000 cGy/6 fr 216 4.1 m 83
3000 cGy/10 fr + 
misonidazole
211 3.9 m 65
3000 cGy/10 fr 212 4.5 m 72
Mehta(23) 3000 cGy/10 fr + MGd 193 5.2 m 82 NR
3000 cGy/10 fr 208 4.9 m 85
RTOG-8905(22) 3750 cGy/15 fr + 
BrdUrd
35 4.3 m 12 63%
3750 cGy/15 fr 37 6.12 m 20 50%
REACH (25) 3000 cGy/10 fr + RSR13 265 5.4 m 119 48%
3000 cGy/10 fr 250 4.4 m 96 36%
RTOG- 0118(26) 3750cGy/15 fr + 
thalidomide
90 NR
3750 cGy/15 fr 93
SMART(24) 3000 cGy/10 fr + MGd 279 NR NR NR
3000 cGy/10 fr 275Page 5 of 11
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Overall mortality in the trials included in this meta-analysis comparing WBRT with radisensitizer to WBRT aloneFigure 2
Overall mortality in the trials included in this meta-analysis comparing WBRT with radisensitizer to WBRT 
alone.
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Local brain tumor response in the trials included in this meta-analysis comparing WBRT with radiosensitizer 
to WBRT alone.
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CNS progression in the trial included in this meta-analysis comparing WBRT with radiosensitizer to WBRT aloneFigure 4
CNS progression in the trial included in this meta-analysis comparing WBRT with radiosensitizer to WBRT 
alone.
Journal of Experimental & Clinical Cancer Research 2009, 28:1 http://www.jeccr.com/content/28/1/1osensitizer BrdU. One death resulted from a severe Ste-
vens-Johnson skin reaction and two other deaths were due
to neutropenia and infection. Mehta et al. reported grade
three and four adverse events: hypotension (5.8%), asthe-
nia (2.6%), hyponatremia (2.1%), leukopenia (2.1%),
hyperglycemia (1.6%), and vomiting (1.6%) in the 193
patients randomized to the whole brain radiotherapy and
motexafin gadolinium arm.
Discussion
In most patients with brain metastasis, WBRT is the main-
stay of treatment and efforts to improve the outcome of
WBRT continue. These efforts include radiation sensitizers
such as efaproxiral, motexafin gadolinium, and thalido-
mide.
Historically, chemical modifiers of radiation effect have
had little impact on overall average survival times in
human trials of brain metastases. Misonidazole, bromo-
deoxyuridine (BUdR), lonidamine, nimustine, fluorour-
acil, and others have failed to show significant benefit in
randomized trials [19-26]. Recent developments suggest a
new interest in this approach with three compounds that
show as a promise as radiosensitizers: motexafin gadolin-
ium, thalidomide and efaproxaril.
Efaproxaril is a small, synthetic molecule that non-cova-
lently binds to hemoglobin and decreases its oxygen bind-
ing affinity and shifts the oxygen dissociation curve to the
left, increasing p50 and tissue pO2. It exerts its effects
based on an increase in tumor oxygen levels, thereby cir-
cumventing restrictions due to the blood brain barrier
[14,28-30] Shaw et al [14] conducted a phase II, open-
label, multicenter study of efaproxaril plus WBRT in 57
patients with brain metastases. The results were retrospec-
tively compared to the RTOG RPA brain metastases data-
base; the average survival time for the efaproxaril treated
patients was 6.4 months compared to 4.1 months for the
database (P < .0174).
Motexafin-gadolinium (MGd) is a metalloporphyrin
redox modulator that demonstrates selective tumor local-
ization and catalyzes the oxidation of a number of intrac-
ellular metabolites, such as ascorbate, glutathione, and
nicotinamide adenine dinucleotide phosphate, thereby
generating reactive oxygen species, and depleting the
pools of reducing agents necessary to repair cytotoxic
damage [31]. Preliminary studies in patients with brain
metastases treated with MGd and WBRT demonstrated
radiological responses in 68% to 72% of patients [31].
Thalidomide inhibits the angiogenic activity of bFGF
(FGF2), a peptide with pleiotropic activities that performs
on various cell types, including endothelial cells, follow-
ing interaction with heparan-sulfate proteoglycans and
tyrosine kinase FGF receptors [32-34]. FGF2 seems to
stimulate both tumor cell growth and angiogenesis
through paracrine mechanisms [33]. Thalidomide can
improve blood flow through tumor neovasculature,
resulting in improved oxygenation and decreased intersti-
tial fluid pressures [34]. Improved tumor oxygenation
during WBRT would improve the therapeutical ratio for
the use of radiation for tumors with hypoxic cells. Thalid-
omide was being given as salvage therapy for recurrent gli-
omas, and a Phase II trial documented that cranial
radiation therapy could be delivered with concomitant
thalidomide administration without unusual toxicity
[35].
The presence of hypoxia in solid tumors has been
acknowledged for over 50 years. Hypoxic cells are more
resistant to standard chemotherapy and radiotherapy, in
addition to being more invasive and metastatic, resistant
to apoptosis, and genetically unstable [36]. Thus, it is not
surprising that hypoxia has been considered an attractive
target for the development of new anti-cancer therapies,
including pro-drugs activated by hypoxia, hypoxia-spe-
cific gene therapy, targeting the hypoxia-inducible factor 1
transcription factor, and recombinant anaerobic bacteria
[38]. The potential to improve local control and survival
by hypoxia modification was demonstrated by a meta-
analysis of 83 clinical trials [38] and a number of thera-
peutical strategies have also been established to overcome
tumor hypoxia by improving oxygen supply either by oxy-
gen or carbogen breathing or by increasing the hemo-
globin level and oxygen delivery [39,40].
Unfortunately, our data, including 7 RCTs with 1.763
patients, using these three promise radiosensitizers com-
bined with WBRT, have not shown a sizeable increase in
average survival (5.2 v 4.9 months; P = 0.48), CNS pro-
gression or local brain tumor response. (9.5 v 8.3 months;
P = 0.95). None of those trials detected any benefit for the-
ses end point mentioned above. In the trial by Mehta et al.
[23], no difference in survival or time to neurological pro-
gression was seen in the use of motexafin gadolinium and
WBRT versus WBRT alone. However, a subgroup analysis,
carried out for lung cancer patients was reported to as an
improvement in neurological progression favoring the
motexafin gadolinium and WBRT arm. The results for the
lung cancer subgroup can only be interpreted as a hypoth-
esis generated as there was no a priori decision to analyze
this group independently. On the basis of these results, a
phase III trial was conducted exclusively in patients with
NSCLC; a preliminary report was presented at the 2006
ASCO meeting. In this international trial, 554 patients
were randomly assigned to WBRT (30 Gy in 10 fractions)
plus MGd (5 mg/kg with each RT treatment) or WBRT
alone [24]. There was a trend to an increased time to neu-
rological progression, the primary endpoint in the study,Page 9 of 11
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alone). In another large RCT study [27], Suh et al. showed
in a subset analysis that the addition of efaproxiral to
WBRT reduced the death rate by 46% (P < 0.0086). Qual-
ity of life was improved in the WBRT with efaproxiral arm
compared to the WBRT alone arm (P = 0.019). Quality-
adjusted survival was statistically and significantly
improved by the addition of efaproxiral to WBRT (P =
0.001).
Patients with brain metastasis may suffer a certain degree
of neurocognitive function (NCF) impairment from mul-
tiple factors including the tumor, WBRT, neurosurgical
procedures, chemotherapy and other neurotoxic therapies
(including anticonvulsants and steroids), or from parane-
oplastic effects induced by the malignancy [41].
Three trials included in this meta-analysis evaluated neu-
rocognitive function. However, we were not able to pool
these data, due to the different methods used for this out-
come. In addition to that, studies involving NCF deterio-
ration should be carefully interpreted. NCF decline in the
literature is often defined statistically and there is little
consensus as to the actual clinical relevance of a statistical
definition. Conventionally, the measures used, such as
the Folstein mini-mental status examination, are rather
crude, and it is crucial to develop sensitive and practical
neurocognitive function testing to characterize these
changes [30]. In particular, the sensitivity of mini-mental
status examination has been shown to be problematical in
detecting subtle neurocognitive dysfunction in patients
with brain metastasis where clinically apparent WBRT-
induced dementia is rare (1.9–5.1%) [42,43]. All of these
factors can potentially affect the manifestation of changes
in neurocognition in a patient with newly developed
brain metastases.
Conclusion
Our results show that WBRT with radiosensitizer have not
improved the overall survival, local control and tumor
response compared to WBRT alone for brain metastases.
Despite the use of WBRT with radiosensitizer, outcomes
are poor and efforts should be made to incorporate mul-
timodality approaches including surgery and radiosurgery
to improve survival. In spite of this apparent negative
result, radiosensitizers may be helpful in specific subsets
of patients with brain metastases from lung and breast
cancers. This can lead to a superior therapeutical ratio by
enhancing the benefit derived from whole brain radio-
therapy resulting in an improvement of neurocognitive
decrease, neurological progression, and quality of life.
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